Home
Scholarly Works
Motexafin gadolinium (MGd) overcomes adverse...
Journal article

Motexafin gadolinium (MGd) overcomes adverse survival effect of anemia in brain metastases (BM) patients treated with whole brain radiation therapy (WBRT): analysis of a phase III randomized trial

Authors

Kumar P; Mehta MP; Rodrigus P; Suh J; Sagar S; Kunkler I; Carrie C; Smith JA; Phan S; Renschler MF

Journal

International Journal of Radiation Oncology • Biology • Physics, Vol. 57, No. 2,

Publisher

Elsevier

Publication Date

October 1, 2003

DOI

10.1016/s0360-3016(03)00838-1

ISSN

0360-3016

Contact the Experts team